Key result
SGLT2 inhibitors reduce cardiovascular mortality and heart failure exacerbations.
Why the study?
Because DM and CVD are major public health challenges and SGLT2 inhibitors show emerging benefits in reducing CVD-related mortality and HF exacerbations, this paper examines existing literature, statistical data, and the pleiotropic effects of SGLT2 inhibitors.
Do SGLT2 inhibitors reduce cardiovascular disease-related mortality and heart failure exacerbations in patients with cardiovascular diseases and diabetes mellitus?
Do SGLT2 inhibitors reduce cardiovascular disease-related mortality and heart failure exacerbations in patients with cardiovascular diseases and diabetes mellitus?
This review highlights the expanding role and market status of SGLT2 inhibitors, particularly dapagliflozin and empagliflozin, in reducing cardiovascular mortality and heart failure exacerbations.
Answers are grounded in this paper and cite their sources.
Supports SGLT2 inhibitor use in diabetes with CV disease; leaves open agent-specific pharmacokinetic optimization.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are revealing new clinical applications beyond the treatment of diabetes mellitus (DM), specifically in reducing the risk of cardiovascular disease (CVD)-related mortality and heart failure (HF) exacerbations. Given that DM and CVD represent major public health challenges and are among the leading causes of long-term disability, this paper aims to examine existing scientific literature and statistical data, as well as to analyze the pleiotropic effects of SGLT2 inhibitors based on currently available evidence and ongoing preclinical studies. Key molecules include dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin, ipragliflozin, and canagliflozin. The latter four are at various stages of their development lifecycle and are not registered in Russia. Canagliflozin increases the risk of lower-limb amputations; due to this proven adverse effect, it is used very rarely, though it remains on the market. Tofogliflozin is currently in the clinical trial phase. Sergliflozin has a total elimination time of no more than one hour; consequently, the drug currently holds little promise. Remogliflozin showed promise, though the project is currently on hold, partly due to competition. Empagliflozin currently leads the overall market, while sales of dapagliflozin are also gaining momentum.
No takes yet. Share an insight, caveat, or question.
Vinogradova et al. (2026) conducted a review in Cardiovascular diseases and diabetes mellitus. Sodium-glucose cotransporter 2 (SGLT2) inhibitors (specifically dapagliflozin) was evaluated on Cardiovascular disease-related mortality and heart failure exacerbations. SGLT2 inhibitors like dapagliflozin reduce cardiovascular mortality and heart failure exacerbations, while sergliflozin has a total elimination time of <=1 hour.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: